Activity Description
Antibody-drug conjugates (ADCs) carry significant ocular risks requiring proactive management. This activity reviews evidence-based strategies for preventing and managing ADC-associated ocular adverse events, including preservative-free artificial tears, topical corticosteroids, and monitoring protocols to optimize patient comfort and treatment adherence.
Sponsored by
The Fundingsland Group, LLC is a COPE-Approved Administrator.
This activity, COPE Activity Number 132798, is accredited by COPE for continuing education for optometrists. This course is approved for 0.5 hours of CE.
Course # 104056-TD
Activity #: 132798
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
Release Date: 05-29-2026
Expiration Date: 05-28-2027
Target Audience
This accredited educational activity is designed for optometrists.
Grant Support Statement
This activity is supported by an unrestricted educational grant from AbbVie.
Faculty
